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Acute lymphoblastic leukemia (ALL) is the most common type of cancer in childhood and its incidence is rising steadily over the past decades. Accumulating evidence from epidemiological studies strongly suggests that the increased leukemia rate is likely related to an abnormal immune response to infections early in life. 1 The identity of the infectious agent in ALL remained elusive, whereas major progress has been achieved in understanding the contribution of infection to aggressive B-cell lymphoma where Plasmodium falciparum, Epstein Barr virus (EBV), Helicobacter pylori, and hepatitis C virus were identified as triggers of transformation. 5, 6 Viruses have been suggested to play a role in the pathogenesis of ALL. Transforming viruses may integrate into the genome of precursor B-cells, disturbing differentiation and proliferation control. 2 Alternatively, common pathogens may act indirectly, eliciting an unusual response in genetically and immunologically susceptible children resulting in autonomous precursor B-cell proliferation. Former attempts to identify candidate viruses by biased, low-throughput techniques were unsuccessful or detected known common human pathogens (reviewed in Table   1 ). Representational difference analysis (RDA), the most sensitive approach so far, achieved a 95% probability of detecting viral genomes larger than 9 kb. But many genomes of oncogenic viruses are smaller (e.g. 5.3 kb Merkel cell polyoma virus or 3.5 kb Rous sarcoma virus genome) and low virus copy numbers, low tumor cell content and subclonality posed additional problems to the limited detection sensitivity of the employed techniques.
In contrast, high-throughput next generation sequencing (NGS) is a highly sensitive approach that has the proven potential to detect known and novel viruses. 7 A recent NGS-based study (Table 1) , that tried to identify viral integration sites in whole genome sequencing data of ten patients with TCF3-rearranged childhood ALL yet failed to detect any true virus/host chimeras. Therefore, we developed a novel bioinformatics pipeline for the detection of viral sequences in data derived from whole genome sequencing that is not restricted to the detection of rare integration sites (Supplemental Figure 1 and Supplemental Methods). First, five data sets derived from the 1000 genomes database (www.1000genomes.org) were used as test sets for the pipeline. More than 25,000 viral genomes deposited in the Genome Information Broker for Viruses database were tested. Probability estimations and in silico simulations demonstrated that the pipeline detects viral genomes (≥2 kb) and viral integration sites with very high probability ( Figure 1A , Supplemental Figure 2 ).
Compared to non-viral genomes, viruses have an increased mutagenesis rate allowing for greater genetic variability and rapid adaptation to changing environments that may be detrimental for sequence identification. We selected ten clinically relevant viruses (simian virus 40, Merkel cell polyoma virus, human 4 papilloma varicella zoster virus, EBV, cytomegalovirus, human immunodeficiency cirus, parvovirus 4, human T-lymphotropic virus-1, Supplemental Table 1 ) ranging from 5.2 to 235.6 kb in genome size and simulated mutation rates of up to 30%. Alignment quality and number of aligned sequencing reads declined with an increasing mutation rate, but virus sequences and integration sites mutated by 10% were still well detectable (>60% for all simulated viruses, Figure 1B and Supplemental Figure 3 ). Virus mutagenesis of 20% became detrimental for the analyses.
We used NGS combined with this pipeline to test whether viral DNA is detectable in 14 pediatric B-cell ALL cases. We chose ETV6-RUNX1-positive (n=7) and high hyperdiploid (n=7) ALL, because these two subtypes are the most frequent ones accounting for 50-60% of all B-cell ALL cases. It is commonly acknowledged that both primary lesions (ETV6-RUNX1-translocation or high hyperdiploidy) are not sufficient to induce overt leukemia. Both subtypes have a long latency period after birth and infection is discussed as a likely transforming trigger. We performed whole genome sequencing for diagnosis, remission and (if applicable) relapse samples. To this end, mononuclear cells were derived by Ficoll density centrifugation from bone marrow, DNA was isolated using standard protocols and sequencing was carried out (Supplementary Material and Methods). On average, we generated 442 million sequencing reads per patient sample (Supplemental Table 2 ). About 10% of these reads could not be mapped to the human reference and may potentially encode viral sequences. As a control data set whole genome sequencing data (comparable in sequencing quality and coverage) of non-leukemic blood samples from 14 age-and gender-matched children were used (chosen from the International Cancer Genome 5 Consortium (ICGC) PedBrain cohort (www.pedbraintumor.org), Supplemental Table   3 ).
Viruses that are integrated into the genome of precursor B-cells may directly promote leukemogenesis by acting on differentiation and proliferation. In this case viral DNA should be persistent and detectable in the leukemic cells. Applying the developed bioinformatics pipeline to the leukemic patient samples, we detected viral DNA in 11 of 14 cases ( Figure 1C , Table 2 ). However, the detected virus sequence corresponded exclusively to known, common human pathogens (Anelloviridae, Herpesviridae, and Parvoviridae). A similar pattern was observed in age-and gender-matched controls. No evidence was found for the presence of other viruses.
Integrated viruses that are truly essential for leukemic cell characteristics can be expected to be persistent at relapse. Persistence of viruses was analyzed in six patients of whom both diagnosis and relapse bone marrow was available. Five patients were positive for at least one virus, but none of these cases presented with the same virus at diagnosis and relapse.
Viruses may promote leukemogenesis indirectly by eliciting an abnormal immunological response resulting in autonomous B-cell precursor proliferation. In this scenario, virus DNA could persist during remission or be solely detectable in remission. Widespread, low-pathogenic viruses may be seen in this case. Similar to the results in leukemic samples, we detected only known common human pathogens in remission samples. Likely due to contaminated blood transfusions, the incidence of Anelloviridae increased from one case at diagnosis to six at remission. Many of the detected viruses were found only at remission and not in the leukemic samples of the same patient. In three patients no viral DNA was identified at any time point.
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Taken together, the analysis of 14 ALL cases, showed that only common human pathogens (Anelloviridae, Herpesviridae, and Parvoviridae) were detected in the majority of B-ALL cases and similar viruses and frequencies were observed in ageand gender-matched controls ( Figure 1C , Supplemental Table 4 , 5, 6, 7). Direct alignment against the viral sequence database or alignment using a Blast-like tool did not alter this result (Supplemental Table 8 , 9, Supplemental Figure 3 Rem.
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Rel. corresponding to common human pathogens (Anelloviridae, Herpesviridae, and Parvoviridae) was detected in 11 of 14 cases. A similar pattern was observed in the age-and gender-matched control cohort. Only HHV7 was more frequently detected in the control cohort (14/14 healthy cases compared to 7/14 ALL cases), but this was not the case in the adult healthy 1000 genomes test set (5/7 cases HHV-7 positive).
Supplemental Supplemental Material and Methods
Patients
Genomic DNA was isolated from bone marrow obtained from 14 pediatric ALL patients (ETV6-RUNX1 positive, n=7; high hyperdiploid, n=7). Presence of the ETV6-RUNX1 fusion gene was confirmed by FISH analysis and RT-PCR, high hyperdiploidy by cytogenetic karyotype analysis. In addition, NGS analysis confirmed the respective ALL subtype. Bone marrow was aspirated at diagnosis, remission and/or relapse. Blast percentage was >70% in the leukemia samples. Mononuclear cells were derived by Ficoll density centrifugation from bone marrow, DNA was isolated using standard protocols and sequencing was carried out as described (1) . The local ethics committee approved the research and written informed consent was given by all parents.
The datasets of the analyzed high hyperdiploid patients were previously used for genomic studies (1, 2 
Data analysis Datasets
Viral reference sequences
In total, 25.525 viral genomes, as deposited in the Genome Information Broker for Viruses (GIB-V) (3), were screened for presence and integration. The dataset contained the genomes of DNA and RNA including several strains and clones of the same organism.
Repeats in viral sequences
Before running the pipeline, the viral sequences were screened for repeats and regions of low complexity with RepeatMasker (4). The coordinates were used for alignment filtering as described below.
Sequence homology between viral and human sequences
All viral sequences were further compared to the human reference genome (GRCh37.55)
with MUMmer (4), which reported regions of high sequence homology between 30 and 9.463bp. Their coordinates were used for alignment filtering as well.
Bioinformatic pipeline
Alignment against human and viral reference genomes
Viral sequence detection starts with the subtraction of all human sequences from the data sets. All reads are aligned to the reference genome, the remaining unmapped reads are candidates for sequences of non-human, viral origin and are extracted from the alignment for further processing. How this first subtraction step is performed is up to the user. We chose BWA (5) in paired-end mode with default parameter settings to map all patient datasets against the human reference genome (GRCh37.55). BWA is a very fast alignment tool, but one may replace it with any other short read aligner.
Next, our pipeline discards potential viral sequences with a similarity of 85% or higher between the viral origin and the human genome. Hence, all previously unmapped reads were aligned in single-end mode once more against the human genome with higher sensitivity and a mapping of minimum 85% of the read with Bowtie2 (6). The scoring and penalty parameter settings were set as follows:
bowtie2 --very-sensitive --mp 1,1 --rdg 2,1 --rfg 2,1 --score-min L,0,-0.15
For this part of the pipeline, we preferred Bowtie2 due to its various parameters, which allow detailed control of multiple alignments (important for the mapping against the virus database) and mapping rates (important for subtraction of human sequences).
The effect of skipping the whole subtraction step i.e. both previous alignments and starting directly with an alignment against the viral genome sequences is shown in Supplemental Table 4 . It demonstrates the importance of a sensitive subtraction of human sequences to avoid false-positive virus detections.
All reads, which were unmapped after the BWA and Bowtie2 alignment, were then aligned against all 25.525 viral sequences simultaneously with Bowtie2.
Since the viral reference contains some highly similar genomes (e.g. clones and strains of the same organism), multiple alignments (up to 1,500) to more than one viral reference sequence were allowed and reported for further analysis (k-mode in Bowtie 2).
bowtie2 -k 1500 -x gib_v_database
A test run with BLAT instead of Bowtie2 for the viral reference alignment is shown in Supplemental Table 5 .
Alignment filtering
Multiple alignments against the same viral sequence and duplicate reads, i.e. alignments of more than one read to the same position, were excluded except for one using Samtools (7). Alignments against viral sequences were then filtered by overlaps with repeat sequences and homologies with human sequences (coordinates were previously computed, as described above). All viruses with at least two alignments were then exported for manual inspection and validation.
Detection of viral integration
All paired-end reads with one alignment on the human genome and one alignment on viral sequences are candidates for viral integration. For that purpose, for every viral alignment, the human alignment was searched for the corresponding partner read. All reads the spanning human and a viral genome were exported for manual inspection and validation.
Simulation of viral sequences and integration
The reference genomes of ten viruses were selected for simulation Human herpesvirus 3 (AJ871403). All virus genomes were randomly mutated with frequencies 0%, 5%, 10%, 15%, 20% and 30%. Positions could not be drawn twice, unannotated regions were excluded and it was assured that a nucleotide was not substituted by the same one. For all the 60 (mutated) genomes, the following two scenarios were simulated:
Viral sequences
This scenario corresponds to the presence of the viral sequences in the DNA without (evidence of) integration (Supplemental Figure 2) . A total of 1,000 non-overlapping 50 bp paired-end reads (i.e. 2,000 sequences) were drawn at random positions from each (mutated) viral genome.
The reads were processed according to our pipeline (including alignment against the human reference genome), and those reads were counted, which could be mapped back against a viral genome of the same type in the GIB-V database.
Viral integration
This second scenario simulates the integration of a viral genome into the host, i.e. a junction between host and viral DNA within the host's genome, which can be detected by a spanning paired-end read across the integration site. For every mutated viral genome, 20 integration sites were picked randomly from chromosome 1 of the human reference genome, giving 40 breakpoints for each virus. Between 80 and 100% of the mutated viral genome was inserted as a whole at each site.
Paired-end reads with 50bp length, 250bp insert-size (50bp standard deviation) and a linear increasing per base error rate were simulated from the modified chromosome 1 using dwgsim (8) with 5x sequence depth. The reads were processed by our pipeline and the sequence coverage and the recall of integration sites was calculated for every virus and mutation frequency.
Theoretical probability of virus detection
The probability for obtaining at least one read from a viral sequence of given length (shown in Fig. 1A ) was computed as
Given a binomial distribution with n experiments (i.e. the number of reads; viral origin: yes/no) and a probability (for hg19). The table presents the viruses detected in ETV6-RUNX1 positive ALL patients. D, diagnosis sample; Rm, remission sample; Rl. relapse sample. Sample-Columns show alignment and coverage against viral genome as number of reads and coverage in bp ("2, 102" i.e. 2 reads, 102 bp coverage). Similarity to other viral genomes: At least 50% of the reads mapped to this viral genome. Filtering steps: 1. Alignment of unmapped reads against the human genome using BOWTIE2: maximum sensitivity and at least 85% sequence similarity. 2. Removal of multiple alignments against the same viral genome. 3. Removal of alignment duplicates (i.e. same position on the same viral genome). 4. Removal of alignments which overlap with repeat regions on the viral genome (previously detected with the program RepeatMasker). 5. Removal of alignments in regions with high sequence similarity to the human genome (previously detected with the program Mummer). 6. Removal of viral genomes with less than 2 alignments. Viruses detected due to similarity to PhiX (detected because of PhiX DNA spike-in in the whole genome sequencing procedure), or similarity to cloning vectors (e.g. HIV gag, pol, env sequences), or viruse not infecting humans were not considered in Table 2 and Figure 1C . 
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